Tian Geng

Tian Geng is a highly experienced scientist specializing in structural biology and crystallography. Currently serving as Lead Scientist at Sosei Heptares since April 2016, Tian Geng leads the development of novel oral anti-viral small molecules targeting SARS-CoV-2, employing advanced crystallography techniques. Prior experience includes roles as Postdoctoral Research Associate at Imperial College London, focusing on the structural studies of G-protein coupled receptors, and research positions at both Imperial College’s Membrane Protein Laboratory and The University of Nottingham. Tian Geng holds a PhD in Structural Biology from Imperial College London and a Master's in Applied Biomolecular Technology from the University of Nottingham.